To ensure the scientific and recognized evaluation of patient-centered clinical research outcomes, the drug development tool qualification certification website of the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research have disclosed the information of clinical outcome assessment (COA) submitted for certification, and encouraged the use of certified COA. This paper searched all COA and approval decisions on the website, analyzed the submitted information and certification status of COA, and interpreted the certification technology and process of COA, so as to provide references and suggestions for the development of patient-centered clinical research outcome evaluation.
Citation：
MA Yucong, JI Zhaochen, ZHANG Chenyao, WU Xiaolei, SHI Menglong, DU Liang, LIU Binglin, CAO Lujia, ZHANG Junhua. Clinical outcome assessment (COA) accreditation methods and progress. Chinese Journal of Evidence-Based Medicine, 2024, 24(8): 974-979. doi: 10.7507/1672-2531.202311163
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
FDA. Patient-focused drug development: collecting comprehensive and representative input guidance for industry, Food and Drug Administration staff, and other stakeholders. 2020.
|
| 2. |
FDA. Patient-focused drug development: methods to identify what is important to patients guidance for industry, Food and Drug Administration staff, and other stakeholders. 2022.
|
| 3. |
FDA. Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. 2022.
|
| 4. |
FDA. Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. 2023.
|
| 5. |
FDA. Qualified clinical outcome assessments (COA). 2021.
|
| 6. |
FDA. Clinical Outcome Assessment (COA) qualification program. 2020.
|
| 7. |
FDA. Division of clinical outcome assessment (DCOA). 2023.
|
| 8. |
|
| 9. |
国家药品监督管理局药品审评中心. 《以患者为中心的临床试验设计技术指导原则(征求意见稿)》. 2022.
|
| 10. |
国家药品监督管理局药品审评中心. 《以患者为中心的临床试验获益-风险评估技术指导原则(征求意见稿)》. 2022.
|
| 11. |
国家药品监督管理局药品审评中心. 《以患者为中心的临床试验实施技术指导原则(征求意见稿)》. 2022.
|
| 12. |
国家药监局药审中心. 关于发布《以患者为中心的药物临床试验设计技术指导原则(试行)》《以患者为中心的药物临床试验实施技术指导原则(试行)》《以患者为中心的药物获益-风险评估技术指导原则(试行)》的通告(2023年第44号). 2023.
|
| 13. |
|
| 14. |
|
| 15. |
|
| 16. |
|
| 17. |
齐欣. 以患者为中心贯穿药研全周期. 医药经济报, 2023.
|
| 18. |
|
| 19. |
|
| 20. |
|
- 1. FDA. Patient-focused drug development: collecting comprehensive and representative input guidance for industry, Food and Drug Administration staff, and other stakeholders. 2020.
- 2. FDA. Patient-focused drug development: methods to identify what is important to patients guidance for industry, Food and Drug Administration staff, and other stakeholders. 2022.
- 3. FDA. Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. 2022.
- 4. FDA. Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. 2023.
- 5. FDA. Qualified clinical outcome assessments (COA). 2021.
- 6. FDA. Clinical Outcome Assessment (COA) qualification program. 2020.
- 7. FDA. Division of clinical outcome assessment (DCOA). 2023.
- 8.
- 9. 国家药品监督管理局药品审评中心. 《以患者为中心的临床试验设计技术指导原则(征求意见稿)》. 2022.
- 10. 国家药品监督管理局药品审评中心. 《以患者为中心的临床试验获益-风险评估技术指导原则(征求意见稿)》. 2022.
- 11. 国家药品监督管理局药品审评中心. 《以患者为中心的临床试验实施技术指导原则(征求意见稿)》. 2022.
- 12. 国家药监局药审中心. 关于发布《以患者为中心的药物临床试验设计技术指导原则(试行)》《以患者为中心的药物临床试验实施技术指导原则(试行)》《以患者为中心的药物获益-风险评估技术指导原则(试行)》的通告(2023年第44号). 2023.
- 13.
- 14.
- 15.
- 16.
- 17. 齐欣. 以患者为中心贯穿药研全周期. 医药经济报, 2023.
- 18.
- 19.
- 20.
